Table 4.

Prevalence of autoantibodies (%) reported in the literature

Principal author	Anti-TPO	Anti-Tm	Anti-Tg	RF	ANA	Anti-SMA	Anti-MA	Anti-IF	Anti-PCA	Age	Number	Population
Present study	0	0	0	38	9	9	1	7	0	≥60	152	Cameroon †
Oyeyinka et al. [2]				9·4	8·3					>65	212	Nigeria ‡
Ricardo et al. [30]					11·4					>65	419	Japan
Azizah et al. [19]					6·9	0	4·9		0·9	31·7(mean)	101	Malasia ‡
Teo et al. [20]				16	33					>65	96	Singapore §
Delepesse et al. [31]		6	8·4		5·1	3·9				57(average)	134	Belgium ¶
Moulias et al. [3]			8		10					≥90	150	France ¶
Chakravarty et al. [32]				10	5	18	13		10	>60	100	UK ‡
Hijmans et al. [33]		17	12	30	18	6	0	0	7	>95	65	the Netherlands ‡
Guiseppina et al. [34]			26		11				18	>71	54	Italy ‡
Velluzzi et al. [35]	9·6									38(mean)	91	Italy ¶
Ruffatti et al. [1]				41·3	15·3					>65	300	Italy ††
Manoussakis et al. [36]				20·2						>67	119	Greece ‡
Manoussakis et al. [4]				14·1	31·1					>67	64	Greece ‡
Perez l et al. [37]				11·8	18·6	16·6	1			>65	102	Spain ‡
Andersen et al. [38]	6·8		5·1							>100	59	Denmark †
Andersen P. [39]					25	10				>60	40	Denmark ‡
Ockhuizen et al. [40]		6			8	0	2		6	>60	51	USA ¶
Roderick et al. [41]				13	19					>65	300	USA ‡
Goodwin et al. [42]				14	18					>65	279	USA ‡
Hallgren et al. [21]			17	21						>60	124	USA ‡
Pandey et al. [5]			8		10				12	>50	727	USA ¶

TPO, thyroid peroxidase; Tm, thyroid microsome; Tg, thyroglobulin; RF, rheumatoid factor; ANA, antinuclear antibody; SMA, smooth muscle antibody; MA, mitochondrial antibody; IF, intrinsic factor; PCA, parietal cell antibody; blanks, not performed.

^†General population

^‡selected individuals based on medical illnesses and drugs

^§patients

^¶healthy

^††selected according to Senieur protocol.